These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18228136)

  • 1. 2-Methoxyestradiol and multidrug resistance: can 2-methoxyestradiol chemosensitize resistant breast cancer cells?
    Azab SS; Salama SA; Abdel-Naim AB; Khalifa AE; El-Demerdash E; Al-Hendy A
    Breast Cancer Res Treat; 2009 Jan; 113(1):9-19. PubMed ID: 18228136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
    Wang TX; Yang XH
    Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of loss of beta 2-microglobulin expression in drug-resistant breast cancer sublines and its involvement in drug resistance.
    Ogretmen B; McCauley MD; Safa AR
    Biochemistry; 1998 Aug; 37(33):11679-91. PubMed ID: 9709006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine.
    Jin J; Wang FP; Wei H; Liu G
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A P-glycoprotein- and MRP1-independent doxorubicin-resistant variant of the MCF-7 breast cancer cell line with defects in caspase-6, -7, -8, -9 and -10 activation pathways.
    Park SJ; Wu CH; Safa AR
    Anticancer Res; 2004; 24(1):123-31. PubMed ID: 15015586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells.
    Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X
    Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
    Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
    Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of cancer multidrug resistance by green tea polyphenols.
    Mei Y; Qian F; Wei D; Liu J
    J Pharm Pharmacol; 2004 Oct; 56(10):1307-14. PubMed ID: 15482646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanism of apoptosis induced by SIRT1 deacetylase inhibitors in human breast cancer MCF-7 drug-resistant cells].
    Li Y; Xu R; Zhang XM; Li DD; He QY
    Yao Xue Xue Bao; 2008 Oct; 43(10):1003-10. PubMed ID: 19127863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circumvention of tumor multidrug resistance by a new annonaceous acetogenin: atemoyacin-B.
    Fu LW; Pan QC; Liang YJ; Huang HB
    Zhongguo Yao Li Xue Bao; 1999 May; 20(5):435-9. PubMed ID: 10678092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells.
    Shen J; Zhang W; Wu J; Zhu Y
    Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin.
    Lukyanova NY; Rusetskya NV; Tregubova NA; Chekhun VF
    Exp Oncol; 2009 Jun; 31(2):87-91. PubMed ID: 19550397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
    Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
    Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
    Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
    Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiologic levels of 2-methoxyestradiol interfere with nongenomic signaling of 17beta-estradiol in human breast cancer cells.
    Vijayanathan V; Venkiteswaran S; Nair SK; Verma A; Thomas TJ; Zhu BT; Thomas T
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2038-48. PubMed ID: 16609013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.